Commodore Capital LP
About Commodore Capital LP’s 13F portfolio
Commodore Capital LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Commodore Capital LP reported $1.7B across 33 US-listed positions (). Its largest position is RELAY THERAPEUTICS INC (RLAY) at 13% of the reported book, and its ten biggest holdings make up 68% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: RLAY RELAY THERAPEUTICS INC | — — | 13% | 12.0M | $224.5M |
| 2 | NASDAQ: ELVN ENLIVEN THERAPEUTICS INC | — — | 9.9% | 3.3M | $166.2M |
| 3 | NASDAQ: ALKS ALKERMES PLC | — — | 9.4% | 3.0M | $157.2M |
| 4 | NASDAQ: COGT COGENT BIOSCIENCES INC | — — | 7.0% | 3.0M | $118.0M |
| 5 | NASDAQ: AMLX AMYLYX PHARMACEUTICALS INC | — — | 6.0% | 5.7M | $101.5M |
| 6 | NASDAQ: DFTX DEFINIUM THERAPEUTICS INC | — — | 5.6% | 2.0M | $94.1M |
| 7 | NASDAQ: SYRE SPYRE THERAPEUTICS INC | — — | 4.5% | 847K | $75.2M |
| 8 | NYSE: ANRO ALTO NEUROSCIENCE INC | — — | 4.3% | 2.7M | $71.9M |
| 9 | NASDAQ: TNGX TANGO THERAPEUTICS INC | — — | 4.2% | 2.3M | $70.3M |
| 10 | NASDAQ: EYPT EYEPOINT INC | — — | 3.9% | 4.6M | $65.8M |
| 11 | NASDAQ: TYRA TYRA BIOSCIENCES INC | — — | 3.6% | 1.9M | $59.9M |
| 12 | NASDAQ: DMRA DAMORA THERAPEUTICS INC | — — | 3.0% | 1.9M | $50.4M |
| 13 | NASDAQ: CLDX CELLDEX THERAPEUTICS INC NEW | — — | 3.0% | 1.4M | $50.2M |
| 14 | NASDAQ: PHVS PHARVARIS N V | — — | 2.9% | 1.4M | $49.3M |
| 15 | NASDAQ: LBRX LB PHARMACEUTICALS INC | — — | 2.9% | 1.5M | $48.7M |
| 16 | NASDAQ: ASMB ASSEMBLY BIOSCIENCES INC | — — | 2.3% | 1.4M | $38.9M |
| 17 | NASDAQ: EDIT EDITAS MEDICINE INC | — — | 1.7% | 8.9M | $28.8M |
| 18 | NASDAQ: KYMR KYMERA THERAPEUTICS INC | — — | 1.7% | 250K | $28.7M |
| 19 | NYSE American: CATX PERSPECTIVE THERAPEUTICS INC | — — | 1.3% | 6.3M | $21.6M |
| 20 | NASDAQ: IPSC CENTURY THERAPEUTICS INC | — — | 1.3% | 8.7M | $21.3M |
| 21 | NASDAQ: ZURA ZURA BIO LTD | — — | 1.1% | 3.3M | $19.2M |
| 22 | NASDAQ: AVTX AVALO THERAPEUTICS INC | — — | 1.1% | 1.0M | $18.8M |
| 23 | NASDAQ: IFRX INFLARX NV | — — | 1.0% | 7.3M | $16.4M |
| 24 | NASDAQ: ANTX AN2 THERAPEUTICS INC | — — | 0.8% | 2.9M | $14.2M |
| 25 | NASDAQ: NUVL NUVALENT INC | — — | 0.7% | 100K | $12.3M |
Showing 1–25 of 33 positions on this page reported in this 13F.
- Healthcare91%
- AddedCOGTCOGENT BIOSCIENCES INC+5.6%$118.0M
- NewTNGXTANGO THERAPEUTICS INC—$70.3M
- AddedEYPTEYEPOINT INC+62.8%$65.8M
- AddedASMBASSEMBLY BIOSCIENCES INC+41.5%$38.9M
- NewEDITEDITAS MEDICINE INC—$28.8M
- AddedAVTXAVALO THERAPEUTICS INC+111%$18.8M
- NewIFRXINFLARX NV—$16.4M
- AddedANTXAN2 THERAPEUTICS INC+25.7%$14.2M
- AddedRLMDRELMADA THERAPEUTICS INC+125%$9.9M
- NewRACCRESEARCH ALLIANCE CORP III—$5.3M
- ReducedRLAYRELAY THERAPEUTICS INC−29.4%$224.5M
- ReducedALKSALKERMES PLC−28.6%$157.2M
- ReducedSYRESPYRE THERAPEUTICS INC−55.7%$75.2M
- ReducedTYRATYRA BIOSCIENCES INC−24.2%$59.9M
- ReducedCLDXCELLDEX THERAPEUTICS INC NEW−49.9%$50.2M
- ReducedPHVSPHARVARIS N V−25.7%$49.3M
- ReducedKYMRKYMERA THERAPEUTICS INC−66.7%$28.7M
- ReducedNUVLNUVALENT INC−88.0%$12.3M
- ReducedSABSSAB BIOTHERAPEUTICS INC−34.8%$11.2M
- SoldOCULOCULAR THERAPEUTIX INC−100%—
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | CATX Perspective Therapeutics, Inc. | 13G | 9.9% · 2 classes | 11.9M | Filed 09 FEB 2026 |
| 2 | SABS SAB Biotherapeutics, Inc. | 13G | 9.9% · 2 classes | 8.9M | Filed 14 AUG 2026 |
| 3 | ANTX AN2 Therapeutics, Inc. | 13G | 9.9% | 3.9M | Filed 16 NOV 2026 |
| 4 | ANRO Alto Neuroscience, Inc. | 13G | 9.9% · 2 classes | 3.6M | Filed 15 MAY 2026 |
| 5 | IPSC Century Therapeutics, Inc. | 13G | 7.1% | 13.0M | Filed 16 JAN 2026 |
| 6 | PEPG PepGen Inc. | 13G | 6.5% · 2 classes | 4.5M | Filed 15 MAY 2026 |
| 7 | TYRA Tyra Biosciences, Inc. | 13G | 6.3% | 3.4M | Filed 14 NOV 2025 |
| 8 | RACC Research Alliance Corp III | 13G | 5.5% | 500K | Filed 28 MAY 2026 |
Showing all 8 disclosed stakes.
Reading Commodore Capital LP’s 13F portfolio
Commodore Capital LP’s $1.7B 13F book is spread across 33 reported positions and is highly concentrated — its ten largest positions alone are 68% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are RLAY, ELVN, ALKS, COGT and AMLX, led by RELAY THERAPEUTICS INC (RLAY) at 13% of the portfolio. The heaviest sector exposure is Healthcare (91%).
What Commodore Capital LP changed last quarter
Between 2026-03-31 and Q2 2026, Commodore Capital LP was a net seller: it opened 5 new positions and added to 6 more, while trimming 9 and closing 8 outright. Against a 33-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was COGENT BIOSCIENCES INC (COGT), and its biggest reduction was RELAY THERAPEUTICS INC (RLAY).
What a 13F does and doesn’t reveal
A 13F captures only Commodore Capital LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Commodore Capital LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Commodore Capital LP's profile on this page is built directly from those filings.
How current is the 13F data on Commodore Capital LP's page?
It reflects Commodore Capital LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Commodore Capital LP files its next quarterly report, this page refreshes automatically.
Can I see Commodore Capital LP's complete list of holdings?
This page highlights Commodore Capital LP's largest positions rather than all 33 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Commodore Capital LP's filings.
Does a 13F show everything Commodore Capital LP owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Commodore Capital LP's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Commodore Capital LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

